Moderna, Inc. (NASDAQ:MRNA) CEO Sells $1,383,750.00 in Stock


Share on StockTwits

Moderna, Inc. (NASDAQ:MRNA) CEO Stephane Bancel sold 9,000 shares of the stock in a transaction that occurred on Wednesday, April 14th. The shares were sold at an average price of $153.75, for a total transaction of $1,383,750.00. Following the completion of the sale, the chief executive officer now directly owns 6,358,868 shares in the company, valued at $977,675,955. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Stephane Bancel also recently made the following trade(s):

  • On Friday, April 9th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $140.91, for a total transaction of $1,556,491.86.
  • On Wednesday, April 7th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $131.63, for a total transaction of $1,184,670.00.
  • On Monday, April 5th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $129.77, for a total transaction of $1,433,439.42.
  • On Wednesday, March 31st, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $121.10, for a total transaction of $1,089,900.00.
  • On Friday, March 26th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $132.76, for a total transaction of $1,466,466.96.
  • On Wednesday, March 24th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $137.07, for a total transaction of $1,233,630.00.
  • On Thursday, March 18th, Stephane Bancel sold 19,000 shares of Moderna stock. The shares were sold at an average price of $146.94, for a total transaction of $2,791,860.00.
  • On Friday, March 12th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $135.73, for a total transaction of $1,499,273.58.
  • On Wednesday, March 10th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $133.24, for a total transaction of $1,199,160.00.
  • On Friday, March 5th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $128.18, for a total transaction of $1,415,876.28.

MRNA stock traded up $10.94 during trading on Friday, hitting $170.81. The company had a trading volume of 18,975,858 shares, compared to its average volume of 11,708,739. The firm has a market capitalization of $68.41 billion, a price-to-earnings ratio of -105.44, a P/E/G ratio of 0.53 and a beta of 1.73. The business has a 50 day moving average of $138.56 and a 200 day moving average of $123.12. Moderna, Inc. has a fifty-two week low of $36.62 and a fifty-two week high of $189.26. The company has a current ratio of 2.43, a quick ratio of 2.43 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.44). The business had revenue of $570.80 million during the quarter, compared to the consensus estimate of $279.41 million. Moderna had a negative return on equity of 28.11% and a negative net margin of 242.73%. Moderna’s revenue was up 3948.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.37) earnings per share. As a group, equities analysts predict that Moderna, Inc. will post -1.5 EPS for the current year.

Several large investors have recently bought and sold shares of the business. Gerber Kawasaki Wealth & Investment Management increased its position in shares of Moderna by 0.9% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 7,420 shares of the company’s stock worth $775,000 after purchasing an additional 65 shares during the last quarter. Simon Quick Advisors LLC boosted its stake in shares of Moderna by 4.7% during the 4th quarter. Simon Quick Advisors LLC now owns 1,570 shares of the company’s stock worth $164,000 after acquiring an additional 70 shares during the period. Carl P. Sherr & Co. LLC boosted its stake in shares of Moderna by 1.4% during the 4th quarter. Carl P. Sherr & Co. LLC now owns 5,227 shares of the company’s stock worth $546,000 after acquiring an additional 74 shares during the period. Harvest Fund Management Co. Ltd boosted its stake in shares of Moderna by 3.2% during the 4th quarter. Harvest Fund Management Co. Ltd now owns 2,876 shares of the company’s stock worth $300,000 after acquiring an additional 90 shares during the period. Finally, Winfield Associates Inc. boosted its stake in shares of Moderna by 2.6% during the 1st quarter. Winfield Associates Inc. now owns 3,925 shares of the company’s stock worth $514,000 after acquiring an additional 100 shares during the period. 51.21% of the stock is currently owned by hedge funds and other institutional investors.

MRNA has been the subject of a number of research analyst reports. Chardan Capital increased their price target on shares of Moderna from $107.00 to $182.00 and gave the company a “buy” rating in a report on Monday, March 8th. Piper Sandler raised their price target on shares of Moderna from $208.00 to $234.00 and gave the stock an “overweight” rating in a research note on Thursday. Oppenheimer raised their price target on shares of Moderna from $178.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, February 1st. Wells Fargo & Company raised their price target on shares of Moderna from $129.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, February 1st. Finally, Brookline Capital Management raised their price target on shares of Moderna from $180.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, March 4th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $152.00.

About Moderna

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.

Featured Article: How to read a candlestick chart

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.